ADVERTISEMENT

Prostate Cancer Surveillance After Radiation Therapy in a National Delivery System

Guideline concordance with PSA surveillance among veterans treated with definitiveradiation therapy was generally high, but opportunities may exist to improve surveillance among select groups.
Federal Practitioner. 2019 February;36(1)s:S16-S21
Author and Disclosure Information

Conclusion

Most veterans receive guideline concordant PSA surveillance after RT for prostate cancer. Nonetheless, at the beginning of treatment, providers should screen veterans for risk factors for loss to follow-up (eg, care at a different or non-VA facility), discuss geographic, financial, and other barriers, and plan to leverage existing VA resources (eg, travel support) to continue to achieve high-quality PSA surveillance and survivorship care. Future research should investigate ways to take advantage of the VA’s robust electronic health record system and telemedicine infrastructure to further optimize prostate cancer survivorship care and PSA surveillance particularly among vulnerable patient groups and those treated outside of their diagnosing facility.

Acknowledgments
Funding Sources: VA HSR&D Career Development Award: 2 (CDA 12−171) and NCI R37 R37CA222885 (TAS).

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.